{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:42:31Z","timestamp":1790030551095,"version":"4.0.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T00:00:00Z","timestamp":1517875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T00:00:00Z","timestamp":1517875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To date poor treatment options are available for patients with congenital pseudarthrosis of the tibia (CPT), a pediatric orphan disease. In this study we have performed an<jats:italic>in silico<\/jats:italic>clinical trial on 200 virtual subjects, generated from a previously established model of murine bone regeneration, to tackle the challenges associated with the small, pediatric patient population. Each virtual subject was simulated to receive no treatment and bone morphogenetic protein (BMP) treatment. We have shown that the degree of severity of CPT is significantly reduced with BMP treatment, although the effect is highly subject-specific. Using machine learning techniques we were also able to stratify the virtual subject population in adverse responders, non-responders, responders and asymptomatic. In summary, this study shows the potential of<jats:italic>in silico<\/jats:italic>medicine technologies as well as their implications for other orphan diseases.<\/jats:p>","DOI":"10.1038\/s41598-018-20737-y","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T10:15:49Z","timestamp":1517393749000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["In silico clinical trials for pediatric orphan diseases"],"prefix":"10.1038","volume":"8","author":[{"given":"A.","family":"Carlier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vasilevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Marechal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Geris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,6]]},"reference":[{"key":"20737_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ymgme.2008.10.003","volume":"1","author":"R Griggs","year":"2009","unstructured":"Griggs, R. et al. Clinical research for rare diseases: opportunities, challenges and solutions. Mol Genet Metab 1, 20\u201326 (2009).","journal-title":"Mol Genet Metab"},{"key":"20737_CR2","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1177\/0883073813495959","volume":"9","author":"E Augustine","year":"2013","unstructured":"Augustine, E., Adams, H. & Mink, J. Clinical Trials in Rare Disease: Challenges and Opportunities. J Child Neurol 9, 1142\u20131150 (2013).","journal-title":"J Child Neurol"},{"key":"20737_CR3","unstructured":"RARE Diseases: Facts and Statistics. Global Genes website https:\/\/globalgenesorg\/rare-diseases-facts-statistics\/AccessedSeptember 2016."},{"key":"20737_CR4","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/bcp.12305","volume":"79","author":"PD Joseph","year":"2013","unstructured":"Joseph, P. D. & Craig, J. C. Clinical trials in children. British Journal of Clinical Pharmacology 79, 357\u2013369 (2013).","journal-title":"British Journal of Clinical Pharmacology"},{"key":"20737_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s10354-015-0423-0","author":"C-H Volmar","year":"2015","unstructured":"Volmar, C.-H., Wahlestedt, C. & Brothers, S. P. Orphan diseases: state of the drug discovery art. Wien Med Wochenschr. https:\/\/doi.org\/10.1007\/s10354-015-0423-0 (2015).","journal-title":"Wien Med Wochenschr"},{"key":"20737_CR6","unstructured":"Viceconti et al. Avicenna Roadmap: in silico clinical trials: how computer simulation will transform the biomedical industry. Research and Technological Development Roadmap, Avicenna Consortium, FP7\/2013-2015\/n\u00b0611819, http:\/\/avicenna-isct.org\/roadmap\/ (2016)."},{"key":"20737_CR7","doi-asserted-by":"crossref","unstructured":"Manolis, E., Rohou, S., Hemmings, R. & Salmonson, T. The Role of Modeling and Simulation in Development and Registration of Medicinal Products: Output From the EFPIA\/EMA Modeling and Simulation Workshop. CPT: Pharmacometrics and Systems Pharmacology 2 (2013).","DOI":"10.1038\/psp.2013.7"},{"key":"20737_CR8","doi-asserted-by":"publisher","unstructured":"Angelis, A., Tordrup, D. & Kanavos, P. Socio-economic burden of rare diseases: A systematic review of cost of illness evidence. Health Policy 964\u2013979, https:\/\/doi.org\/10.1016\/j.healthpol.2014.12.016 (2015).","DOI":"10.1016\/j.healthpol.2014.12.016"},{"key":"20737_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-016-0464-5","author":"R-D Hilgers","year":"2016","unstructured":"Hilgers, R.-D., Roes, K. & Stallard, N. Directions for new developments on statistical design and analysis of small population group trials. Orphanet Journal of Rare Diseases. https:\/\/doi.org\/10.1186\/s13023-016-0464-5 (2016).","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"20737_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.18203\/2349-3259.ijct20161408","volume":"3","author":"M Viceconti","year":"2016","unstructured":"Viceconti, M., Henney, A. & Morley-Fletcher, E. In silico clinical trials: how computer simulation will transform the biomedical industry. International Journal of Clinical Trials 3, 37\u201346 (2016).","journal-title":"International Journal of Clinical Trials"},{"key":"20737_CR11","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.pbiomolbio.2007.07.019","volume":"96","author":"J Southern","year":"2008","unstructured":"Southern, J. et al. Multi-scale computational modelling in biology and physiology. Progress in Biophysics and Molecular Biology 96, 60\u20139 (2008).","journal-title":"Progress in Biophysics and Molecular Biology"},{"key":"20737_CR12","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.bone.2007.11.006","volume":"42","author":"A Schindeler","year":"2008","unstructured":"Schindeler, A. & Little, D. G. Recent insights into bone development, homeostasis, and repair in type 1 neurofibromatosis (NF1). Bone 42, 616 (2008).","journal-title":"Bone"},{"key":"20737_CR13","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s11832-012-0421-3","volume":"6","author":"B Dohin","year":"2012","unstructured":"Dohin, B. & Kohler, R. Masquelet\u2019s procedure and bone morphogenetic protein in congenital pseudarthrosis of the tibia in children: a case series and meta-analysis. Journal of Children\u2019s Orthopaedics 6, 297\u201306 (2012).","journal-title":"Journal of Children\u2019s Orthopaedics"},{"key":"20737_CR14","doi-asserted-by":"publisher","unstructured":"Richards, S. & Anderson, T. rhBMP-2 and Intramedullary Fixation in Congenital Pseudarthrosis of the Tibia. Journal of Pediatric Orthopaedics 1 https:\/\/doi.org\/10.1097\/BPO.0000000000000789.","DOI":"10.1097\/BPO.0000000000000789"},{"key":"20737_CR15","unstructured":"FDA Warning: Avoid Using Bone Growth Products in Children. https:\/\/wwwschmidtlawcom\/fda-warning-avoid-using-bone-growth-proteins-in-children\/accessed april 2017."},{"key":"20737_CR16","doi-asserted-by":"crossref","unstructured":"Carlier, A. et al. Capturing the wide variety of impaired fracture healing phenotypes in Neurofibromatosis Type 1 with eight key factors: a computational study. Scientific Reports 7 (2016).","DOI":"10.1038\/srep46384"},{"key":"20737_CR17","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1302\/0301-620X.93B5.25938","volume":"93B","author":"A Spiro","year":"2011","unstructured":"Spiro, A. et al. Combined treatment of congenital pseudarthrosis of the tibia, including recombinant human bone morphogenetic protein-2. The Journal of Bone and Joint Surgery 93B, 695\u2013699 (2011).","journal-title":"The Journal of Bone and Joint Surgery"},{"key":"20737_CR18","doi-asserted-by":"crossref","first-page":"627","DOI":"10.2106\/00004623-200603000-00023","volume":"88A","author":"FY-I Lee","year":"2006","unstructured":"Lee, F. Y.-I. et al. Treatment of Congenital Pseudarthrosis of the Tibia with Recombinant Human Bone Morphogenetic Protein-7 (rhBMP-7). The Journal of Bone and Joint Surgery 88A, 627\u2013633 (2006).","journal-title":"The Journal of Bone and Joint Surgery"},{"key":"20737_CR19","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jtbi.2014.10.012","volume":"365","author":"A Carlier","year":"2015","unstructured":"Carlier, A., Geris, L., van Gastel, N., Carmeliet, G. & Van Oosterwyck, H. Oxygen as a critical determinant of bone fracture healing\u2014A multiscale model. Journal of Theoretical Biology 365, 247\u2013264 (2015).","journal-title":"Journal of Theoretical Biology"},{"key":"20737_CR20","doi-asserted-by":"crossref","unstructured":"Carlier, A., van Gastel, N., Geris, L., Carmeliet, G. & Van Oosterwyck, H. Size does matter: an integrative in vivo-in silico approach for the treatment of critical size bone defects. PLoS Comput Biol 10 (2014).","DOI":"10.1371\/journal.pcbi.1003888"},{"key":"20737_CR21","doi-asserted-by":"crossref","unstructured":"Geris, L., Vander Sloten, J. & Van Oosterwyck, H. Occurrence and Treatment of Bone Atrophic Non-Unions Investigated by an Integrative Approach. PLoS Comput Biol 6 (2010).","DOI":"10.1371\/journal.pcbi.1000915"},{"key":"20737_CR22","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1097\/01.CCM.0000142394.28791.C3","volume":"32","author":"G Clermont","year":"2004","unstructured":"Clermont, G. et al. design of clinical trials: A method coming of age. Crit Care Med 32, 2061\u20132070 (2004).","journal-title":"Crit Care Med"},{"key":"20737_CR23","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1007\/s00198-016-3597-4","volume":"27","author":"M Qasim","year":"2016","unstructured":"Qasim, M. et al. Patient-specific finite element estimated femur strength as a predictor of the risk of hip fracture: the effect of methodological determinants. Osteoporos Int 27, 2815\u20132822 (2016).","journal-title":"Osteoporos Int"},{"key":"20737_CR24","doi-asserted-by":"crossref","unstructured":"Harnisch, L. & Shepard, T. Modeling and Simulation as a Tool to Bridge Efficacy and Safety Data in Special Populations. CPT: Pharmacometrics and Systems Pharmacology 2 (2013).","DOI":"10.1038\/psp.2013.6"},{"key":"20737_CR25","doi-asserted-by":"publisher","unstructured":"Martelli, S. et al. Biomechanical robustness of a new proximal epiphyseal hip replacement to patient variability and surgical uncertainties: A FE study. Medical Engineering & Physics 161\u20131, https:\/\/doi.org\/10.1016\/j.medengphy.2011.07.006 (2012).","DOI":"10.1016\/j.medengphy.2011.07.006"},{"key":"20737_CR26","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1016\/j.hrthm.2013.10.009","volume":"10","author":"BL Wilkoff","year":"2013","unstructured":"Wilkoff, B. L. et al. Safe magnetic resonance imaging scanning of patients with cardiac rhythm devices_ A role for computer modeling. Heart Rhythm 10, 1815\u20131821 (2013).","journal-title":"Heart Rhythm"},{"key":"20737_CR27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1177\/193229680900300106","volume":"3","author":"B Kovatchev","year":"2009","unstructured":"Kovatchev, B., Breton, M., Man, C. D. & Cobelli, C. Preclinical Trials: A Proof of Concept in Closed-Loop Control of Type 1 Diabetes. Journal of Diabetes Science and Technology 3, 44\u201355 (2009).","journal-title":"Journal of Diabetes Science and Technology"},{"key":"20737_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphys.2013.00358","volume":"4","author":"P Pathmanathan","year":"2013","unstructured":"Pathmanathan, P. Ensuring reliability of safety-critical clinical applications of computational cardiac models. Frontiers in Physiology 4, 1\u20136 (2013).","journal-title":"Frontiers in Physiology"},{"key":"20737_CR29","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1056\/NEJMra1512592","volume":"376","author":"J Drazen","year":"2017","unstructured":"Drazen, J., Harrington, D., McMurray, J., Ware, J. & Woodcock, J. An FDA Viewpoint on Unique Considerations for Medical-Device Clinical Trials. The New England Journal of Medicine 376, 1350\u20131357 (2017).","journal-title":"The New England Journal of Medicine"},{"key":"20737_CR30","doi-asserted-by":"crossref","unstructured":"Stevenson, D. A. et al. Double inactivation of NF1 in tibial pseudarthrosis. The American Journal of Human Genetics 143\u2013148 (2006).","DOI":"10.1086\/504441"},{"key":"20737_CR31","doi-asserted-by":"publisher","unstructured":"Sant, D. W. et al. Evaluation of somatic mutations in tibial pseudarthrosis samples in neurofibromatosis type 1. Journal of Medical Genetics 256\u2013261, https:\/\/doi.org\/10.1136\/jmedgenet-2014-102815 (2015).","DOI":"10.1136\/jmedgenet-2014-102815"},{"key":"20737_CR32","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1046\/j.1523-1747.1999.00609.x","volume":"112","author":"RP Atit","year":"1999","unstructured":"Atit, R. P., Crowe, M. J., Greenhalgh, D. G., Wenstrup, R. J. & Ratner, N. The Nf1 Tumor Suppressor Regulates Mouse Skin Wound Healing, Fibroblast Proliferation, and Collagen Deposited by Fibroblasts. Journal of Investigative Dermatology 112, 835\u2013842 (1999).","journal-title":"Journal of Investigative Dermatology"},{"key":"20737_CR33","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/jbmr.528","volume":"27","author":"J El-Hoss","year":"2012","unstructured":"El-Hoss, J. et al. A Murine Model of Neurofibromatosis Type 1 Tibial Pseudarthrosis Featuring Proliferative Fibrous Tissue and Osteoclast-like Cells. Journal of Bone and Mineral Research 27, 68\u201378 (2012).","journal-title":"Journal of Bone and Mineral Research"},{"key":"20737_CR34","doi-asserted-by":"crossref","unstructured":"Kolanczyk, M. et al. Modelling neurofibromatosis type 1 tibial dysplasia and its treatment with lovastatin. BMC Medicine 6 (2008).","DOI":"10.1186\/1741-7015-6-21"},{"key":"20737_CR35","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.actbio.2011.06.021","volume":"7","author":"A Carlier","year":"2011","unstructured":"Carlier, A. et al. Designing optimal calcium phosphate scaffold-cell combinations using an integrative model-based approach. Acta Biomaterialia 7, 3573\u20133585 (2011).","journal-title":"Acta Biomaterialia"},{"key":"20737_CR36","doi-asserted-by":"publisher","unstructured":"Isaksson, H., van Donkelaar, C. C., Huiskes, R., Yao, J. & Ito, K. Determining the most important cellular characteristics for fracture healing using design of experiments methods. Journal of Theoretical Biology 26\u201339, https:\/\/doi.org\/10.1016\/j.jtbi.2008.07.037 (2008).","DOI":"10.1016\/j.jtbi.2008.07.037"},{"key":"20737_CR37","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/j.addr.2003.08.010","volume":"55","author":"M Geiger","year":"2003","unstructured":"Geiger, M., Li, R. H. & Friess, W. Collagen sponges for bone regeneration with rhBMP-2. Advanced Drug Delivery Reviews 55, 1613\u20131629 (2003).","journal-title":"Advanced Drug Delivery Reviews"},{"key":"20737_CR38","doi-asserted-by":"publisher","first-page":"4856","DOI":"10.1016\/j.biomaterials.2005.01.012","volume":"26","author":"Y Takahashi","year":"2005","unstructured":"Takahashi, Y., Yamamoto, M. & Tabata, Y. Enhanced osteoinduction by controlled release of bone morphogenetic protein-2 from biodegradable sponge composed of gelatin and b-tricalcium phosphate. Biomaterials 26, 4856\u20134865 (2005).","journal-title":"Biomaterials"},{"key":"20737_CR39","unstructured":"R Core Team R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http:\/\/www.R-project.org\/ (2013)."},{"issue":"3","key":"20737_CR40","first-page":"18","volume":"2","author":"A Liaw","year":"2002","unstructured":"Liaw, A. et al. Classification and Regression by randomForest. R News 2(3), 18\u201322 (2002).","journal-title":"R News"},{"key":"20737_CR41","unstructured":"Kuhn, M. Contributions from Jed Wing, Steve Weston, Andre Williams, Chris Keefer, Allan Engelhardt, Tony Cooper, Zachary Mayer, Brenton Kenkel, the R Core Team, Michael Benesty, Reynald Lescarbeau, Andrew Ziem, Luca Scrucca, Yuan Tang and Can Candan. Caret: classification and regression training, R package, version 6.0\u201371 (2016)."},{"key":"20737_CR42","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1093\/bioinformatics\/btq166","volume":"26","author":"S Kembel","year":"2010","unstructured":"Kembel, S. et al. Picante: R tools for integrating phylogenies and ecology. Bioinformatics 26, 1463\u20131464 (2010).","journal-title":"Bioinformatics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-20737-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-20737-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-20737-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T19:36:59Z","timestamp":1693510619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-20737-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,6]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["20737"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-20737-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,6]]},"assertion":[{"value":"1 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"2465"}}